Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Heron Therapeutics Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is far larger — about 43.8× Heron Therapeutics Inc's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Heron Therapeutics Inc for 35 Days on average.
| FNGU | HRTX | |
|---|---|---|
Market Cap | $2.98B | $68.01M |
Volume | 4,682,352 | 1,891,941 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $1.49 |
52-Week Low | $13.73 | $0.27 |
Typical Hold Time | 19 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $35.99, down 3.25% today. Technical indicators show a bullish trend with strong moving average support but neutral oscillators. The ETN faces significant volatility risks as highlighted by recent analysis showing it lost 87% during previous tech sector downturns. Support levels cluster around $33-35 with resistance at $37-39.
While leveraged exposure to AI leaders like Nvidia and Meta offers upside potential during tech rallies, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the potential for amplified returns against the documented vulnerability to sector corrections, requiring careful risk management in portfolio allocation.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
